Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2137 - 2144 of 12104 results
Health Law Diagnosed – The Regulatory Landscape of Value-Based Primary Care: Top 5 Matters for Aledade’s Regulatory Counsel
November 4, 2022| Podcast| Viewpoint
NYC Proposes Rules in Advance of 2023 Automated Employment Decision Tools Law
November 4, 2022| Blog| Viewpoint
Last Call: Public Comments on Inflation Reduction Act Clean Energy Tax Incentives Are Requested By November 4
November 3, 2022| Alert| Viewpoint
RIAs Beware: The Pitfalls When Going Straight To The (Out)Source
November 3, 2022| Blog| Viewpoint
Connecticut Joins the Interstate Medical Licensure Compact and the Psychology Interjurisdictional Compact
November 3, 2022| Blog| Viewpoint
Ruling May Spur New Patent Venue Rows Over Remote Work
November 3, 2022| News
Mintz Attorneys Help Fuel Equitable Growth at the Bizgrow Conference
November 2, 2022| Article| Viewpoint
SEC Adopts Amendments Requiring Electronic Filing of Forms 144
November 2, 2022| Alert| Viewpoint
News & Press Releases
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|